Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Summary

The purpose of this study is to evaluate the safety of an investigational drug called azeliragon and determine the safest dose to treat patients with metastatic pancreatic cancer. The study will examine the effects of azeliragon on patients and their pain (if any). Azeliragon may have the potential to slow down the development and growth of pancreatic cancer cells in the body; it will be provided to participants as a hard gelatin capsule.


Inclusion Criteria

  • Patient must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, such as resection of an isolated metastasis, are not available.
  • Patient should have previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen.
  • Toxicity from prior chemotherapy other than alopecia has recovered to Grade ≤ 1 (CTCAE 1.0) or are at baseline (such as stable G2 neuropathy).
  • Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age.
Show more

Study Location(s)

  • Cedars-Sinai Cancer at Beverly Hills (THO) : Abrahm Levi
  • Cedars-Sinai Cancer at SOCC : Abrahm Levi


More about this Clinical Trial

Full Title

CAN-201: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Details
Disease Type/Condition

Pancreas

Principal Investigator

Hendifar, Andrew

Co-Investigators

Arsen Osipov, David Hoffman, Jeremy Lorber, Jun Gong, Kamya Sankar, Kevin Scher

Age Group

Adult

Phase

I/II

IRB Number

STUDY00002298

ClinicalTrials.gov ID

NCT05766748

Key Eligibility
ClinicalTrials.gov

Contact
Name

Abrahm Levi

Phone
310-423-2133
Email
Abrahm.Levi@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Pancreas

Principal Investigator

Hendifar, Andrew

Age Group

Adult

Phase

I/II

IRB Number

CAN-201

ClinicalTrials.gov ID

NCT05766748

Key Eligibility
ClinicalTrials.gov

Contact
Name

Abrahm Levi

Phone
310-423-2133
Email
Abrahm.Levi@cshs.org
Want to join the study or
learn more?